ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$84.14M

FY 2025 · Annual

Investing Cash Flow

$82.59M

FY 2025 · Annual

-4.3% YoY

Financing Cash Flow

$362,000.00

FY 2025 · Annual

-98.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.46M)(123.48M)(160.81M)(134.85M)(101.7M)
Depreciation & Amortization51K342K836K872K706K
Deferred Income Tax00000
Stock-Based Compensation13.91M23.84M26.27M27.09M12.58M
Change in Working Capital(4.03M)9.85M8.3M(12.43M)336K
Accounts Receivables00000
Inventory00000
Accounts Payables3.29M4.51M458K(4.02M)421K
Other Working Capital(7.32M)5.34M7.84M(8.41M)(85K)
Other Non-Cash Items5.42M228K(4.97M)(2.6M)3.93M
Operating Cash Flow(68.1M)(89.22M)(130.36M)(121.91M)(84.14M)
Capital Expenditures(4.92M)(1.43M)(1.27M)(447K)(212K)
Acquisitions (Net)0233.99K000
Purchases of Investments0(376.79M)(246.63M)(107.41M)(51.59M)
Sales of Investments0142.8M292.56M194.11M134.39M
Other Investing Activities0(233.99K)000
Investing Cash Flow(4.92M)(235.42M)44.66M86.26M82.59M
Debt Repayment(281K)9.61M(388K)(827K)(1.36M)
Common Stock Issued2.75M903K58.89M31.64M1.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(655K)792K00
Financing Cash Flow2.47M9.86M59.29M30.82M362K
Effect of Forex Changes00000
Net Change in Cash(70.55M)(314.78M)(26.42M)(4.84M)(1.19M)
Free Cash Flow(73.02M)(90.65M)(131.64M)(122.36M)(84.35M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$101.7M
+ D&A$706.0K
+ Stock-Based Comp$12.6M
+ Deferred Tax$0
+ Working Capital$336.0K
+ Other Non-Cash$3.9M
= Operating Cash Flow-$84.1M
- Capex-$212.0K
= Free Cash Flow-$84.4M

Analysis

FY2025 free cash flow is -$84.4M. FCF conversion is 82.9% of net income. Operating cash flow was -$84.1M, with capex of -$212.0K. The largest bridge item is Stock-Based Comp at $12.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingOct 16, 2026
8-KCurrent reportOct 15, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does ALXO generate free cash flow?

ALX Oncology Holdings Inc. (ALXO) generated -$84.35M of free cash flow in fiscal 2025.

How much operating cash flow does ALXO produce?

Operating cash flow was -$84.14M, before capital expenditures of $212,000.00.